Johnson & Johnson’s Office of the Chief Medical Officer (OCMO) works to ensure that the safety data underpinning all our product are scientifically sound and robust; following from that, it is also an OCMO priority to provide healthcare practitioners, physicians, surgeons, patients and consumers with the most informative data and understanding of the safety of our products so that they may make well informed healthcare decisions.
To that end, Johnson & Johnson Innovation and the OCMO are looking to reward up to $200,000 in multiple grants, and one year of JLABS space, to the individuals or teams who submit the best ideas on how to educate, inform and provide clarity around healthcare product safety.
Empowering patients and consumers to make more informed healthcare decisions by providing better information and education about the safety of healthcare products (pharmaceuticals, medical devices and consumer products).
This challenge focus area seeks ways to maximize consumer and patient education and understanding of healthcare products and their safety and efficacy, including medical devices, pharmaceuticals and consumer products.
The objective is to empower patients, consumers and healthcare providers to make more informed decisions and obtain maximum benefit from product use through greater understanding of safety data and by ensuring more effective communication and enhancing education.
Improving training and development for surgeons by identifying new models that simulate the operating room environment.
This focus area seeks new and robust models and methods to evaluate medical devices used by surgeons in a simulated environment representative of operating room procedures, with the goal of helping the surgeon understand how to safely and effectively use a medical device and understand variability in device and performance/outcome.
Entries should focus on soft tissue models that anatomically represent organ-specific anatomic features and biological properties, such as tissue injury, bleeding and clotting responses.
Empowering patients and consumers to more safely administer and handle healthcare products.
The third focus area seeks ways to address the challenge of prescription medication errors. Entries should identify patient- and consumer-focused devices, solutions or platforms that will prevent errors and solutions to promote safe storage and administration or extend the shelf life of prescription, over-the-counter or cosmetic products.
True benefit from healthcare products requires an unrelenting focus on patient- and consumer-centered safety, a principle that is at the heart of Johnson & Johnson’s Credo and is embodied in the mission of the Office of the Chief Medical Officer (OCMO). Working to ensure that J&J is developing and making available the safest products possible is what the nearly 1000 employees of OCMO work towards each day. Always looking for better ways to address safety on behalf of patients and consumers, we are embarking on a Quickfire Challenge to identify new and innovative ideas to increase the safe use of our products.
Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
Deadline to apply is May 24, 2017
Winner(s) will be announced in November
Send us your application!Apply now
Established in 2013, the Johnson & Johnson Office of the Chief Medical Officer (OCMO) is accountable for bringing scientific excellence, bioethics- and values-driven decision-making, as well as a commitment to transparency and medical safety assessments that are independent of commercial interests, to the many efforts that keep patients and consumers at the heart of everything we do. The OCMO has oversight across Johnson & Johnson for medical safety, epidemiology, R&D operations and creating and maintaining global bioethical policies.
Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.
Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.
JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018). For more information about JLABS, please visit www.jlabs.jnjinnovation.com.
You can find our press release here.